Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
74High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07653685CT.gov A Clinical Study of TQB2930 Injection and Chemotherapy With or Without Bevacizumab in the Treatment of Advanced Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07281768CT.gov Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07622550CT.gov A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Serplulimab and Chemotherapy as First-line Treatment for Patients With RAS/BRAF-mutated Advanced Colorectal Cance | — | Not Yet Recruiting | — | — | — |
NCT07318389CT.gov ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07621497CT.gov FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II) | — | Not Yet Recruiting | — | — | — |
NCT07595276CT.gov Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status. | — | Not Yet Recruiting | — | — | — |
NCT07570914CT.gov Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases | — | Not Yet Recruiting | — | — | — |
NCT07500298CT.gov Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT07462143CT.gov A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT07503756CT.gov JS212 Combination Therapies in Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
Show 442 more trialsShow fewer
NCT07412613CT.gov Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer | — | Recruiting | — | — | — |
NCT07094893CT.gov Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status | — | Not Yet Recruiting | — | — | — |
NCT07365592CT.gov Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC | — | Recruiting | — | — | — |
NCT07474727CT.gov A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07503639CT.gov Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07448142CT.gov Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer | — | Recruiting | — | — | — |
NCT07284849CT.gov A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer | — | Recruiting | — | — | — |
NCT07446465CT.gov FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07229846CT.gov A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation | — | Not Yet Recruiting | — | — | — |
NCT07323576CT.gov A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer | — | Withdrawn | — | — | — |
NCT07243938CT.gov Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET) | — | Not Yet Recruiting | — | — | — |
NCT07150403CT.gov Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07221357CT.gov A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT07318805CT.gov A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT07283367CT.gov A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients. | — | Recruiting | — | — | — |
NCT07268677CT.gov A Single-arm Clinical Study Evaluating Pirfenidone and Sintilimab in Combination With Standard Neoadjuvant Chemotherapy for Colorectal Cancer Patients With Peritoneal Metastasis. | — | Not Yet Recruiting | — | — | — |
NCT06948448CT.gov A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer | — | Recruiting | — | — | — |
NCT07228832CT.gov Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT07233850CT.gov A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers | — | Not Yet Recruiting | — | — | — |
NCT07407465CT.gov Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer. | — | Recruiting | — | — | — |
NCT07167446CT.gov Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy | — | Recruiting | — | — | — |
NCT07389265CT.gov Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT06501989CT.gov Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer | — | Withdrawn | — | — | — |
NCT07284992CT.gov SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC | — | Recruiting | — | — | — |
NCT07334587CT.gov Comparison of Efficacy and Safety Between FOLFOX-6 and CAPOX in Metastatic Colorectal Carcinoma | — | Enrolling By Invitation | — | — | — |
NCT07106034CT.gov Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial | — | Not Yet Recruiting | — | — | — |
NCT07154316CT.gov Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer | — | Recruiting | — | — | — |
NCT07309289CT.gov NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT07025239CT.gov QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT06696768CT.gov Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT06959693CT.gov A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC) | — | Not Yet Recruiting | — | — | — |
NCT06963502CT.gov A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors | — | Not Yet Recruiting | — | — | — |
NCT07020468CT.gov Neoadjuvant Therapy （NALIRIFOX） for Locally Advanced Colon and Upper Rectal Cancer | — | Active Not Recruiting | — | — | — |
NCT07204574CT.gov The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT03401294CT.gov Conversion From Unresectable To Resectable Metastatic Colorectal Cancer. | — | Recruiting | — | — | — |
NCT06820463CT.gov A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT06885385CT.gov A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer | — | Recruiting | — | — | — |
NCT06922383CT.gov A Clinical Study of Arfolitixorin in Patients With mCRC | — | Recruiting | — | — | — |
NCT06899477CT.gov Pre-Operative Treatment in REseCTable COlon CanceR | — | Not Yet Recruiting | — | — | — |
NCT06917079CT.gov BBO-11818 in Adult Subjects With KRAS Mutant Cancer | — | Recruiting | — | — | — |
NCT06245356CT.gov Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer | — | Recruiting | — | — | — |
NCT06835569CT.gov A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations | — | Recruiting | — | — | — |
NCT06848465CT.gov LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis | — | Recruiting | — | — | — |
NCT06835179CT.gov SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer. | — | Not Yet Recruiting | — | — | — |
NCT06475352CT.gov Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme | — | Recruiting | — | — | — |
NCT06791512CT.gov mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC | — | Recruiting | — | — | — |
NCT06621563CT.gov Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT04516681CT.gov Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT06268015CT.gov Botensilimab and Balstilimab Optimization in Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT06733038CT.gov FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients. | — | Recruiting | — | — | — |
NCT06625775CT.gov Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06607185CT.gov A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT06090994CT.gov Prevention of Recurrence and Metastasis of Colorectal Cancer by Comparing Huaier With Capecitabine Monotherapy | — | Recruiting | — | — | — |
NCT06825624CT.gov ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT06596343CT.gov Evaluating the Benefits of Personalized Traditional Chinese Medicine in Postoperative Treatment for Locally Advanced Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT06616259CT.gov First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study | — | Not Yet Recruiting | — | — | — |
NCT06598007CT.gov A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06586515CT.gov MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors | — | Recruiting | — | — | — |
NCT06493760CT.gov A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients | — | Recruiting | — | — | — |
NCT06550453CT.gov Safety and Efficacy of Pembrolizumab in Combination with Bevacizumab + CapeOX in the Neoadjuvant Treatment of RAS-mutated, BRAF Wild-type, Microsatellite-stabilized, Locally Advanced Colorectal Cancer | — | Recruiting | — | — | — |
NCT06575127CT.gov Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study | — | Recruiting | — | — | — |
NCT06504901CT.gov Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases | — | Not Yet Recruiting | — | — | — |
NCT06275958CT.gov DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT06324357CT.gov Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread | — | Recruiting | — | — | — |
NCT06881537CT.gov CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer | — | Recruiting | — | — | — |
NCT06856447CT.gov The Role of Coenzyme Q10 in the Prophylaxis of Oxaliplatin Induced Peripheral Neuropathy in Patients With Colorectal Cancer | — | Recruiting | — | — | — |
NCT06415851CT.gov Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab | — | Unknown | — | — | — |
NCT06328738CT.gov ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT06445062CT.gov Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | — | Recruiting | — | — | — |
NCT06441565CT.gov Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer | — | Recruiting | — | — | — |
NCT06423937CT.gov Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT06405139CT.gov Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal Cancer | — | Recruiting | — | — | — |
NCT06192680CT.gov Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT06225622CT.gov Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT06106308CT.gov Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation | — | Active Not Recruiting | — | — | — |
NCT06225843CT.gov Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis | — | Recruiting | — | — | — |
NCT06280495CT.gov Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients | — | Recruiting | — | — | — |
NCT06566755CT.gov Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer | — | Recruiting | — | — | — |
NCT07391163CT.gov Protective Effect of N-acetylcysteine on Oxaliplatin-Induced Neuropathy in Colorectal Cancer | — | Completed | — | — | — |
NCT06765616CT.gov Adebrelimab Injection (PD-L1) Combined With Short Course Radiotherapy and Chemotherapy for Neoadjuvant Therapy of Locally Advanced Rectal Cancer | — | Recruiting | — | — | — |
NCT06039202CT.gov Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT06011772CT.gov EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT05839470CT.gov Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer | — | Unknown | — | — | — |
NCT05959356CT.gov Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT05803382CT.gov Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers | — | Recruiting | — | — | — |
NCT06099951CT.gov Total Neoadjuvant Treatment for pMMR Locally Advanced Low Rectal Cancer: Anti-PD-1 Antibody With FOLFOXIRI and Preoperative Radiation Therapy | — | Not Yet Recruiting | — | — | — |
NCT05863195CT.gov Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial | — | Recruiting | — | — | — |
NCT05985707CT.gov KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT05945901CT.gov A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT05954078CT.gov Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer | — | Recruiting | — | — | — |
NCT05948072CT.gov Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM | — | Not Yet Recruiting | — | — | — |
NCT05571644CT.gov Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer | — | Recruiting | — | — | — |
NCT05970302CT.gov XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC | — | Recruiting | — | — | — |
NCT06516445CT.gov SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC | — | Recruiting | — | — | — |
NCT05919264CT.gov FOG-001 in Locally Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT05846867CT.gov A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT05627635CT.gov FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT05585814CT.gov CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer | — | Recruiting | — | — | — |
NCT05861505CT.gov COLLISION RELAPSE Trial | — | Recruiting | — | — | — |
NCT05652894CT.gov A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT05721872CT.gov Efficacy, Tolerability and Safety of Intravenous D-VC With ATO in Patients With Advanced/Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT05775900CT.gov Efficacy and Safety of Triweekly Cetuximab in Combination With Capecitabine as First-line Maintenance Treatment for KRAS/BRAF Wild-type Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT05634590CT.gov The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT05590117CT.gov Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer | — | Unknown | — | — | — |
NCT05427669CT.gov Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD) | — | Not Yet Recruiting | — | — | — |
NCT06048146CT.gov A Prospective, Multicenter Randomized Controlled Study of the Application of Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Low- and Medium-lying Rectal Cancer With Lateral Lymph Node Metastasis | — | Completed | — | — | — |
NCT05489211CT.gov Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) | — | Recruiting | — | — | — |
NCT05524155CT.gov Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis | — | Unknown | — | — | — |
NCT05480306CT.gov Phase 2 Study of DKN-01 in Colorectal Cancer | — | Completed | — | — | — |
NCT05464030CT.gov Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) | — | Recruiting | — | — | — |
NCT05378867CT.gov A Study Assessing the Interchangeability Between TRS003 and Bevacizumab® For CRC | — | Unknown | — | — | — |
NCT05379595CT.gov A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT05480280CT.gov mFOLFOX6 Combined With Dalpiciclib in Patients With Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT05239650CT.gov Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC | — | Not Yet Recruiting | — | — | — |
NCT05435313CT.gov Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy | — | Unknown | — | — | — |
NCT05355701CT.gov A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. | — | Recruiting | — | — | — |
NCT05451719CT.gov Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy | — | Unknown | — | — | — |
NCT05382442CT.gov A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT05364489CT.gov Efficacy, Safety and Exploratory Clinical Study of Bevacizumab Combined With Oxaliplatin and TAS-102 in First-line Treatment of Advanced Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT05600309CT.gov A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study | — | Completed | — | — | — |
NCT05343013CT.gov TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy | — | Recruiting | — | — | — |
NCT05353582CT.gov Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases | — | Unknown | — | — | — |
NCT05544812CT.gov A Small-sample, Real-world Study of Sintilimab Plus Bevacizumab/Cetuximab Plus XELOX Regimen for Conversion Therapy in Patients With Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT05314101CT.gov TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer | — | Unknown | — | — | — |
NCT05978349CT.gov PTC Drug Sensitivity Detection to Guide Postoperative Adjuvant of Colorectal Cancer | — | Unknown | — | — | — |
NCT05091528CT.gov A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers | — | Terminated | — | — | — |
NCT05171660CT.gov Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT05511051CT.gov A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With HAIC in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic Therapy | — | Unknown | — | — | — |
NCT05200299CT.gov mFOLFOXIRI Compared to mFOLFOX6 or CapeOx as Adjuvant Chemotherapy for Stage IIIB or IIIC Colorectal Cancer | — | Unknown | — | — | — |
NCT03678428CT.gov FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM | — | Terminated | — | — | — |
NCT05008809CT.gov Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418) | — | Recruiting | — | — | — |
NCT05039944CT.gov SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies | — | Terminated | — | — | — |
NCT04991948CT.gov Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT04952753CT.gov Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC | — | Terminated | — | — | — |
NCT05064059CT.gov A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) | — | Completed | — | — | — |
NCT05103020CT.gov Phase II Study Comparing Conversion Rate to Surgery With Hepatic Arterial Infusion Chemotherapy to Systemic Chemotherapy in Patients With Non Resectable Liver-only Colorectal Metastases | — | Unknown | — | — | — |
NCT02942706CT.gov Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC | — | Unknown | — | — | — |
NCT04929223CT.gov A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) | — | Recruiting | — | — | — |
NCT04847063CT.gov Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies | — | Recruiting | — | — | — |
NCT05068206CT.gov A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx | — | Unknown | — | — | — |
NCT05266820CT.gov Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT06540261CT.gov The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT05116891CT.gov A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT05074966CT.gov The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts | — | Unknown | — | — | — |
NCT05030493CT.gov An Additional Analysis of Data From the PARADIGM Exploratory Study (NCT02394834) in Patients With Advanced/Recurrent Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT05093907CT.gov A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT04920032CT.gov Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas | — | Recruiting | — | — | — |
NCT05022030CT.gov First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes | — | Unknown | — | — | — |
NCT04793958CT.gov Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) | — | Active Not Recruiting | — | — | — |
NCT04868773CT.gov Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy | — | Completed | — | — | — |
NCT04999761CT.gov AB122 Platform Study | — | Recruiting | — | — | — |
NCT04854668CT.gov A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT06206096CT.gov PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC | — | Unknown | — | — | — |
NCT04660812CT.gov An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. | — | Completed | — | — | — |
NCT04761614CT.gov Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT04194359CT.gov Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT04687631CT.gov Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases | — | Recruiting | — | — | — |
NCT06547385CT.gov Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT04835142CT.gov Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC | — | Completed | — | — | — |
NCT04668976CT.gov A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma | — | Unknown | — | — | — |
NCT04534218CT.gov Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT04659382CT.gov Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT04145193CT.gov Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC | — | Withdrawn | — | — | — |
NCT04525326CT.gov Conversion Therapy of RAS/BRAF Wild-Type Right-sided Colon Cancer Patients With Initially Unresectable Liver Metastases | — | Unknown | — | — | — |
NCT04164069CT.gov Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab | — | Completed | — | — | — |
NCT04230187CT.gov Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT04421820CT.gov BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours | — | Recruiting | — | — | — |
NCT04456699CT.gov Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003) | — | Completed | — | — | — |
NCT04301557CT.gov PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT04337879CT.gov A Study of AL2846 Capsule Combined With Standard Chemotherapy Regimen in Subjects With Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT04513951CT.gov AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients | — | Completed | — | — | — |
NCT04338191CT.gov mFOLFOXIRI Versus mFOLFOX6 as Adjuvant Chemotherapy for Locally Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT03228043CT.gov Apatinib for Resectable Colorectal Cancer | — | Withdrawn | — | — | — |
NCT04126655CT.gov Modelle 001, TS-inhibition in Colorectal Liver Metastases Comparing Arfolitixorin and Calciumfolinate | — | Unknown | — | — | — |
NCT04233151CT.gov QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and Safety | — | Unknown | — | — | — |
NCT04080843CT.gov Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients | — | Completed | — | — | — |
NCT04304209CT.gov Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer | — | Active Not Recruiting | — | — | — |
NCT04068610CT.gov COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC | — | Active Not Recruiting | — | — | — |
NCT04324476CT.gov A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT04008030CT.gov A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) | — | Active Not Recruiting | — | — | — |
NCT04160416CT.gov mXELOXIRI Combined With Molecular Targeted Drug in mCRC | — | Unknown | — | — | — |
NCT04008511CT.gov Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT03366155CT.gov Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver | — | Completed | — | — | — |
NCT03984578CT.gov Window of Opportunity Study in Colorectal Cancer | — | Completed | — | — | — |
NCT03950154CT.gov Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT03798626CT.gov Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers | — | Completed | — | — | — |
NCT03974594CT.gov Bioequivalence Study of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients | — | Completed | — | — | — |
NCT03626922CT.gov Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients | — | Unknown | — | — | — |
NCT03854799CT.gov Immunotherapy In Locally Advanced Rectal Cancer | — | Completed | — | — | — |
NCT03869892CT.gov Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy. | — | Active Not Recruiting | — | — | — |
NCT03775525CT.gov Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer | — | Unknown | — | — | — |
NCT03717038CT.gov Sym004 Versus TAS-102 in Patients With mCRC | — | Withdrawn | — | — | — |
NCT03813641CT.gov RALOX or CAPOX + Bevacizumab in the First-line Treatment of Advanced CRC(ROCB Study) | — | Unknown | — | — | — |
NCT03750786CT.gov A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT03721653CT.gov FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients | — | Completed | — | — | — |
NCT03692429CT.gov alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells | — | Recruiting | — | — | — |
NCT03720678CT.gov A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies | — | Completed | — | — | — |
NCT03645876CT.gov SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT03795311CT.gov Evaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in Patients With Colorectal Cancer (FOLFIRINOX 3) | — | Active Not Recruiting | — | — | — |
NCT03693807CT.gov A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma | — | Completed | — | — | — |
NCT03530267CT.gov Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer | — | Completed | — | — | — |
NCT03376659CT.gov Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma | — | Terminated | — | — | — |
NCT03169777CT.gov QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC | — | Withdrawn | — | — | — |
NCT03686254CT.gov The Effects of RFA in Combination With Second-line Chemotherapy and Bevacizumab on Unresectable CRLM | — | Unknown | — | — | — |
NCT03547999CT.gov A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC | — | Terminated | — | — | — |
NCT03597581CT.gov A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT03565029CT.gov Total Neoadjuvant Treatment Without Surgery For Locally Advanced Rectal Cancer | — | Completed | — | — | — |
NCT03668418CT.gov Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos | — | Unknown | — | — | — |
NCT03500874CT.gov Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM | — | Terminated | — | — | — |
NCT03186326CT.gov Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer | — | Completed | — | — | — |
NCT03396926CT.gov Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer | — | Completed | — | — | — |
NCT03493048CT.gov Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM | — | Active Not Recruiting | — | — | — |
NCT03426371CT.gov Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial | — | Terminated | — | — | — |
NCT03374254CT.gov Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651) | — | Completed | — | — | — |
NCT03493061CT.gov A Study of Systemic Chemotherapy With CPT-11 Plus HAI (FUDR+L-OHP) in Patients With Initially Unresectable CRCLM | — | Completed | — | — | — |
NCT03377842CT.gov Apatinib Treatment as the Neoadjuvant Therapy in Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT02997228CT.gov Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study | — | Active Not Recruiting | — | — | — |
NCT05316818CT.gov Triplet (FOLFOXIRI) vs. Doublet (FOLFOX or FOLFIRI) Regimen as a 1st Line Treatment in Metastatic Colorectal Carcinoma | — | Completed | — | — | — |
NCT03280511CT.gov Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients | — | Recruiting | — | — | — |
NCT03314935CT.gov A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors | — | Completed | — | — | — |
NCT03223779CT.gov Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer | — | Completed | — | — | — |
NCT03176264CT.gov PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer | — | Terminated | — | — | — |
NCT03117972CT.gov Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels | — | Terminated | — | — | — |
NCT03222089CT.gov Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC | — | Withdrawn | — | — | — |
NCT02873195CT.gov Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT02758951CT.gov Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases | — | Active Not Recruiting | — | — | — |
NCT03050814CT.gov Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004 | — | Terminated | — | — | — |
NCT03126071CT.gov Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT03504618CT.gov Research on the Treatment of Metastatic Colon Cancer Patients Treated by FOLFOXIRI | — | Completed | — | — | — |
NCT03035253CT.gov A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT02980510CT.gov Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients | — | Active Not Recruiting | — | — | — |
NCT02955940CT.gov An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib | — | Active Not Recruiting | — | — | — |
NCT04034459CT.gov FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC | — | Unknown | — | — | — |
NCT02978313CT.gov Cetuximab Monotherapy Maintenance Treatment in mCRC | — | Unknown | — | — | — |
NCT02861300CT.gov CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer | — | Completed | — | — | — |
NCT02860546CT.gov A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC | — | Completed | — | — | — |
NCT02785146CT.gov Adjuvant Chemotherapy Combined With Huaier Granule for Treating High-risk Stage II, Stage III Colorectal Cancer | — | Unknown | — | — | — |
NCT02591667CT.gov Histopathological Response to FOLFOXIRI + Bevacizumab in Peritoneal Metastasis From Colorectal Cancer | — | Unknown | — | — | — |
NCT02512172CT.gov A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT02654639CT.gov Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT03210298CT.gov International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | — | Unknown | — | — | — |
NCT02413853CT.gov Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer | — | Withdrawn | — | — | — |
NCT02574663CT.gov TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors | — | Completed | — | — | — |
NCT02515734CT.gov A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab | — | Unknown | — | — | — |
NCT02415699CT.gov DC-CIK Immunotherapy Plus Chemotherapy vs Chemotherapy Alone in the Adjuvant Treatment of Stage III Colorectal Cancer | — | Unknown | — | — | — |
NCT02503150CT.gov Trial of Antigen Pulsed Dendritic Cells (APDC) in Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT02476045CT.gov Panitumumab-based Maintenance in Patients With RAS Wild-type, Metastatic Colorectal Cancer (Valentino) | — | Unknown | — | — | — |
NCT02375672CT.gov Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT02494973CT.gov Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases | — | Completed | — | — | — |
NCT02497157CT.gov Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT02291289CT.gov A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) | — | Completed | — | — | — |
NCT02934529CT.gov Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab | — | Completed | — | — | — |
NCT02280694CT.gov Low Dose Metronomic Poly-chemotherapy for Metastatic CRC | — | Completed | — | — | — |
NCT02415829CT.gov Efficacy and Safety of Oxaliplatin Combined With Capecitabine as Neoadjuvant Chemotherapy for Locally Advanced Colon Cancer Patients | — | Unknown | — | — | — |
NCT01889680CT.gov Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer | — | Withdrawn | — | — | — |
NCT02251977CT.gov Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Stage II/III Colorectal Cancer | — | Completed | — | — | — |
NCT02178722CT.gov Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | — | Completed | — | — | — |
NCT02162563CT.gov Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases | — | Completed | — | — | — |
NCT02141295CT.gov A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT02128425CT.gov FOLFOXIRI Compared to FOLFOX in First Line Treatment of Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT02083653CT.gov Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT02102789CT.gov A Study of Systemic Chemotherapy With/Without HAI in Patients With Initially Unresectable Colorectal Liver Metastasis | — | Unknown | — | — | — |
NCT02688023CT.gov Neoadjuvant Triplet Chemotherapy Regimen in Patients With Resectable Colorectal Cancer | — | Unknown | — | — | — |
NCT02068131CT.gov Recombinant Anti-tumor and Anti-virus Protein for Injection Plus Xeloda in Treatment of Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT01858662CT.gov Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors | — | Terminated | — | — | — |
NCT01876511CT.gov Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C) | — | Completed | — | — | — |
NCT01955837CT.gov Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia | — | Completed | — | — | — |
NCT01786538CT.gov Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines | — | Withdrawn | — | — | — |
NCT01834014CT.gov Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases | — | Completed | — | — | — |
NCT02210364CT.gov Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC). | — | Completed | — | — | — |
NCT01803282CT.gov Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01802645CT.gov Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases | — | Unknown | — | — | — |
NCT01832948CT.gov Endostar Combined With mFOLFOX6 for First-line Treatment of Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT01646554CT.gov Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases | — | Withdrawn | — | — | — |
NCT01718808CT.gov Cetuximab for Elderly Patients With mCRC | — | Terminated | — | — | — |
NCT01705002CT.gov Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors. | — | Completed | — | — | — |
NCT01506167CT.gov An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN) | — | Completed | — | — | — |
NCT02821559CT.gov Biweekly Versus Triweekly Raltitrexed With Oxaliplatin (With or Without Bevacizumab) in First-line Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT01715363CT.gov Feasibility of an Immediate Preoperative Chemotherapy Before Resection fo Colorectal Cancer | — | Terminated | — | — | — |
NCT01607957CT.gov Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies | — | Completed | — | — | — |
NCT03084809CT.gov Chemotherapy Combined With CIK Treating Colon Cancer | — | Completed | — | — | — |
NCT01867697CT.gov Nordic 8 - A Phase II Trial | — | Completed | — | — | — |
NCT01898104CT.gov Preoperative Valproic Acid and Radiation Therapy for Rectal Cancer | — | Unknown | — | — | — |
NCT01571024CT.gov BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer | — | Completed | — | — | — |
NCT01776307CT.gov A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT01531595CT.gov Study of Bevacizumab in Combination with Alternating XELIRI and XELOX in Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT01490866CT.gov A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC) | — | Completed | — | — | — |
NCT01478594CT.gov A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy | — | Completed | — | — | — |
NCT01399684CT.gov A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT01529164CT.gov Efficacy and Safety Study of Recombinant Endostatin Combined With Chemotherapy to Treat Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT01418222CT.gov FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT02720926CT.gov Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Advanced Colorectal and Gastric Cancer | — | Terminated | — | — | — |
NCT01420874CT.gov Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer) | — | Completed | — | — | — |
NCT01532804CT.gov 2nd-line Treatment of Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT01338558CT.gov A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Naïve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab | — | Withdrawn | — | — | — |
NCT01321957CT.gov Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT01328171CT.gov FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI) | — | Completed | — | — | — |
NCT01327612CT.gov Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) | — | Completed | — | — | — |
NCT01293942CT.gov IXO+A in mCRC With Liver-only Metastases | — | Withdrawn | — | — | — |
NCT01442935CT.gov Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases | — | Completed | — | — | — |
NCT01276379CT.gov Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab | — | Completed | — | — | — |
NCT01348412CT.gov Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure | — | Completed | — | — | — |
NCT01442649CT.gov Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab | — | Completed | — | — | — |
NCT01228734CT.gov A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients | — | Completed | — | — | — |
NCT01167725CT.gov Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer | — | Terminated | — | — | — |
NCT01260415CT.gov A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases | — | Completed | — | — | — |
NCT01161316CT.gov Safety and Efficacy Study of mFOLFOX-6 Plus Cetuximab for 8 Cycles Followed by mFOLFOX-6 Plus Cetuximab or Single Agent Cetuximab as Maintenance Therapy in Patients With Metastatic Colorectal Cancer and WT KRAS Tumours | — | Completed | — | — | — |
NCT01193517CT.gov Azacitidine and CAPOX in Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT01150045CT.gov Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery | — | Completed | — | — | — |
NCT01099449CT.gov Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy | — | Completed | — | — | — |
NCT01047293CT.gov RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma | — | Completed | — | — | — |
NCT01097018CT.gov Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT01280643CT.gov Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT01071655CT.gov Selecting Treatment in Colorectal Cancer:Capecitabine or 5-fluorouracil Selection to be Combined With Oxaliplatin or Irinotecan as First-line Chemotherapy in Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT00803647CT.gov A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver | — | Completed | — | — | — |
NCT01067053CT.gov Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients. | — | Unknown | — | — | — |
NCT00997685CT.gov Evaluate Efficacy and Safety of XELOX in Potentially Resectable Liver Metastasis From Colorectal Cancer(CRC) | — | Unknown | — | — | — |
NCT00959647CT.gov A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study | — | Completed | — | — | — |
NCT01030042CT.gov Trial Comparing Two Two Sequences of Therapy in Colorectal Metastatic Patients | — | Completed | — | — | — |
NCT01110941CT.gov Feasibility Study of SOL (S-1,Oral Leucovorin,and Oxaliplatin) for Colorectal Cancer in China | — | Completed | — | — | — |
NCT00959946CT.gov Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT01035385CT.gov Compare FOFLOX4 in Preoperative and Postoperative and Postoperative in Resectable Liver Metastasis Colorectal Cancer (MCC) | — | Unknown | — | — | — |
NCT01077739CT.gov A Study of Avastin (Bevacizumab) With XELOX or FOLFOX in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI and Avastin | — | Completed | — | — | — |
NCT00975897CT.gov Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT01437618CT.gov First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00940303CT.gov OPAL Study: A Study of Avastin (Bevacizumab) in Combination With FOLFOXIRI in Patients With Previously Untreated Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00873756CT.gov A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00851136CT.gov A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g) | — | Completed | — | — | — |
NCT00885885CT.gov Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases | — | Completed | — | — | — |
NCT00890305CT.gov Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone | — | Completed | — | — | — |
NCT00920868CT.gov XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib | — | Completed | — | — | — |
NCT01225744CT.gov Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy | — | Completed | — | — | — |
NCT00866944CT.gov Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases | — | Completed | — | — | — |
NCT00869570CT.gov External-Beam Radiation Therapy, Capecitabine, and Sorafenib in Treating Patients With Locally Advanced Rectal Cancer | — | Completed | — | — | — |
NCT00686166CT.gov S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer | — | Completed | — | — | — |
NCT00778830CT.gov Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study) | — | Completed | — | — | — |
NCT00853684CT.gov Oxaliplatin, Capecitabine and Endostar as First Line Treatment for Patients With Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT00755534CT.gov Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC | — | Terminated | — | — | — |
NCT00755118CT.gov Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc | — | Terminated | — | — | — |
NCT00779311CT.gov A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT00778102CT.gov A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer. | — | Completed | — | — | — |
NCT00707889CT.gov Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT00700570CT.gov A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00852228CT.gov Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy | — | Unknown | — | — | — |
NCT00721916CT.gov Randomized Phase II Study of SOL for Untreated Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00677443CT.gov Study of S-1 and Oxaliplatin (SOX) Versus Capecitabine and Oxaliplatin (COX) in Patients With Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT00636610CT.gov A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00642603CT.gov A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT00660582CT.gov FLOX + Cetuximab (Erbitux®) for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor | — | Completed | — | — | — |
NCT00784446CT.gov First-line Therapy of Stage IV Colorectal Cancer | — | Completed | — | — | — |
NCT00577031CT.gov OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum. | — | Completed | — | — | — |
NCT00874406CT.gov Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer | — | Unknown | — | — | — |
NCT00479752CT.gov Safety and Efficacy of Folfox4 + Weekly Cetuximab vs Folfox 4+Biweekly Cetuximab by Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00551213CT.gov A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003) | — | Completed | — | — | — |
NCT00531115CT.gov Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With XELOX for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer. | — | Terminated | — | — | — |
NCT00541112CT.gov Radiation Therapy, Chemotherapy, and Cetuximab Followed by Surgery, Chemotherapy, and Cetuximab in Treating Patients With Locally Advanced or Metastatic Rectal Cancer That Can Be Removed by Surgery | — | Terminated | — | — | — |
NCT01271166CT.gov Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer | — | Terminated | — | — | — |
NCT00625651CT.gov Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00574171CT.gov Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma | — | Completed | — | — | — |
NCT00524706CT.gov Phase I/II Study of SOL for Untreated Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT00835185CT.gov Study of IMC-11F8 in Participants With Colorectal Cancer | — | Completed | — | — | — |
NCT00640081CT.gov Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00689624CT.gov Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal Cancer | — | Completed | — | — | — |
NCT00513266CT.gov Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery | — | Unknown | — | — | — |
NCT00494221CT.gov A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX | — | Completed | — | — | — |
NCT00537823CT.gov Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement | — | Terminated | — | — | — |
NCT00766142CT.gov Chemotherapy and Cetuximab in Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer | — | Terminated | — | — | — |
NCT00492999CT.gov Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver | — | Active Not Recruiting | — | — | — |
NCT00501410CT.gov FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00500292CT.gov A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer | — | Completed | — | — | — |
NCT00482222CT.gov Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer | — | Unknown | — | — | — |
NCT00438737CT.gov Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer | — | Unknown | — | — | — |
NCT01135498CT.gov A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer. | — | Completed | — | — | — |
NCT00399035CT.gov Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00544349CT.gov Leucovorin, Fluorouracil, Cetuximab, and Oxaliplatin in Treating Patients With Stage IV Colorectal Cancer and Liver Metastases That Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT00514761CT.gov Phase II Efficacy Study of AZD6244 in Colorectal Cancer | — | Completed | — | — | — |
NCT00384176CT.gov First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX | — | Completed | — | — | — |
NCT00349336CT.gov A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer. | — | Completed | — | — | — |
NCT00532909CT.gov Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00478946CT.gov A Study of Picoplatin in Colorectal Cancer | — | Unknown | — | — | — |
NCT00316745CT.gov IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer | — | Suspended | — | — | — |
NCT00305643CT.gov Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer | — | Terminated | — | — | — |
NCT00290615CT.gov Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery | — | Completed | — | — | — |
NCT00278889CT.gov Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX) | — | Completed | — | — | — |
NCT00268463CT.gov Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer | — | Terminated | — | — | — |
NCT01159171CT.gov A Study of Avastin (Bevacizumab) and Oxaliplatin Plus Xeloda (Capecitabine) in Patients With Advanced Colorectal Cancer. | — | Completed | — | — | — |
NCT00343408CT.gov AZD2171 and Standard Combination Chemotherapy in Advanced Non-Small Cell Lung Cancer or Colorectal Cancer | — | Completed | — | — | — |
NCT00265811CT.gov Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed By Surgery | — | Completed | — | — | — |
NCT03362684CT.gov PETACC-8 miR-31-3p and miR-31-5p Ancillary Study | — | Completed | — | — | — |
NCT00408551CT.gov Chemotherapy and Internal Radiation in Treating Patients With Colorectal Cancer That Has Spread to the Liver | — | Unknown | — | — | — |
NCT00265850CT.gov Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00252564CT.gov Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00383695CT.gov Oxaliplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients Undergoing Surgery for High-Risk Rectal Cancer | — | Unknown | — | — | — |
NCT00556413CT.gov Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00538291CT.gov Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment | — | Terminated | — | — | — |
NCT00125034CT.gov Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC) | — | Completed | — | — | — |
NCT00353262CT.gov A Study of Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Metastatic Colorectal Cancer. | — | Completed | — | — | — |
NCT00286130CT.gov Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00208546CT.gov Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT01131078CT.gov A Study of Avastin (Bevacizumab) in Combination Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum | — | Completed | — | — | — |
NCT00145314CT.gov FLOX in Combination With Cetuximab in First-line Treatment of Colorectal Cancer | — | Completed | — | — | — |
NCT00199797CT.gov Phase I Trial of huA33 Plus Chemotherapy in Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00182715CT.gov Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT00202787CT.gov Safety and Efficacy Study of Combination Therapy With Cetuximab and FOLFOX4 in Patients With Colorectal Cancer | — | Completed | — | — | — |
NCT00107250CT.gov AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07) | — | Completed | — | — | — |
NCT00868816CT.gov Oxaliplatine Based Adjuvant Chemotherapy for Stage II/III Colorectal Cancer: 8 Cycles Versus 12 Cycles | — | Completed | — | — | — |
NCT00103298CT.gov Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer | — | Completed | — | — | — |
NCT00081224CT.gov Neoadjuvant Celecoxib and Capecitabine Combined With Pelvic Irradiation in Treating Patients With Stage II or Stage III Adenocarcinoma (Cancer) of the Rectum | — | Terminated | — | — | — |
NCT00056030CT.gov Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer | — | Completed | — | — | — |
NCT00153998CT.gov Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM) | — | Completed | — | — | — |
NCT00254137CT.gov Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer. | — | Completed | — | — | — |
NCT00070434CT.gov S0304 Induct Chemo Then Chemo-RT in Pts w/Locally Advanced Adenocarcinoma of the Rectum | — | Withdrawn | — | — | — |
NCT00226941CT.gov A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer | — | Terminated | — | — | — |
NCT00227734CT.gov Capecitabine and Oxaliplatin With or Without Cetuximab in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery | — | Completed | — | — | — |
NCT00444678CT.gov Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00208260CT.gov Intensified Chemotherapy in CRC After Resection of Liver Metastases | — | Completed | — | — | — |
NCT00262808CT.gov GM-CSF and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Colon Cancer | — | Completed | — | — | — |
NCT00081237CT.gov OSI-7904L and Oxaliplatin in Treating Patients With Refractory or Recurrent Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT00087334CT.gov Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT01196260CT.gov Combination Chemotherapy Treatments in Patients With Colorectal Cancer Stage II and III | — | Unknown | — | — | — |
NCT00077233CT.gov FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum | — | Terminated | — | — | — |
NCT00819754CT.gov A Phase I/II Study of IXO With Bevacizumab in Patients With Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT00072553CT.gov Celecoxib, Leucovorin, Fluorouracil, and Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT00069095CT.gov A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00069108CT.gov A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00230399CT.gov Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00192075CT.gov A Randomized Trial of Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid Versus Avastin + Oxaliplatin + 5FU/Folinic Acid in Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00064181CT.gov Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00123851CT.gov Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00061815CT.gov Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer | — | Completed | — | — | — |
NCT00059930CT.gov Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer | — | Completed | — | — | — |
NCT00055822CT.gov Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT00268398CT.gov Combination Chemotherapy in Treating Patients With Colorectal Cancer and Resectable Metastases | — | Completed | — | — | — |
NCT00258232CT.gov Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT01219920CT.gov FOLFOXIRI Compared With FOLFIRI for Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00026299CT.gov Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer | — | Completed | — | — | — |
NCT00025142CT.gov Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer | — | Completed | — | — | — |
NCT00008294CT.gov Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer | — | Completed | — | — | — |
NCT00005050CT.gov Eniluracil, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT00006050CT.gov Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver | — | Completed | — | — | — |
NCT00034619CT.gov A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer. | — | Completed | — | — | — |
NCT00571740CT.gov Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Oxaliplatin (this asset) | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Approved | BB · 70 |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Marble Dust | James Varani | P2/3 | BB |
| Orectalip | Sinphar Pharmaceutical Co., Ltd | P4 | BB |
| Fluorouracilum | UNICANCER | P4 | BB |
| Levofolinic Acid | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BB |
| Fentanyl | Mansoura University | P4 | BB |
| Panitumumab | MSPU des 3 Provinces | P3 | BB |
| Arfolitixorin | Isofol Medical AB | P3 | BB |
+42 more in the Colorectal Cancer cohort
Other indications for Oxaliplatin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Exocrine Pancreatic Carcinoma | — | P2/3 | BBB · 76 |
| Colon Adenocarcinoma | — | P3 | BBB · 76 |
| Colorectal Neoplasm | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Oxaliplatin in Colorectal Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 13, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/oxaliplatin-colorectal-cancer-116181
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →